Neoadjuvant mitomycin C showed a favorable safety profile with mild to moderate side effects, including hematuria, dysuria, and itchy scalp. The trial did not show significant improvement in 12-month ...

Infiltration and extravasation are one of the most destructive complications to the neonate's fragile skin. This article reviews multiple aspects of infiltration and extravasation injury.

Jessica MacIntyre's compassionate care and expertise were pivotal in Camille Moses's successful cancer treatment journey. At Sylvester Comprehensive Cancer Center, Jessica has developed programs ...

for UGN-102 (mitomycin) for intravesical solution, an investigational treatment for recurrent LG-IR-NMIBC. The ODAC meeting will provide an opportunity for independent clinicians and other experts ...

Jelmyto showed a 47.8-month median duration of response for low-grade upper tract urothelial cancer in a long-term follow-up. UGN-102 achieved a median 24.2-month duration of response in recurrent ...

UGN-102 is UroGen’s sustained-release formulation of mitomycin being developed for the treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

Continence care takes centre stage in the May 2025 issue of Nursing Times. The annual conference of the Association for Continence Professionals (ACP) takes place later this month in Milton Keynes.

WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today ...

Doxorubicin is a type of anthracycline chemotherapy drug used to treat certain types of solid tumors and blood cancers. It has a number of side effects, some more serious than others. Experts ...

If you have bladder cancer, there are several treatment options. Your doctor will help you decide which one is best for you. Choosing the best treatment depends on a number of things, including ...